In order to guarantee your privacy on this website and not leave any trace of your activity, please note the following:
1. There's a "Quick Exit" button to exit immediately.
2. When you open a PDF, simply view it, without saving it.
3. Make sure you clear your browsing history before you leave.
4. Use private or incognito browsing.
Search engine
Approximately 90% of cancer-related deaths occur due to patient relapses or resistance to treatments. Oniria Therapeutics offers ONR-001, an innovative oral drug that over-activates the TET2 tumor suppressor, causing the cancer cells to die. In pre-clinical trials it’s displayed a high degree of efficacy and tolerability in cases of melanoma, colorectal tumors and acute myeloid leukemia.
Contact
